Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) COO Jr. Michael Conick Hanley sold 70,000 shares of the stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $27.68, for a total value of $1,937,600.00. Following the completion of the sale, the chief operating officer directly owned 17,729 shares of the company’s stock, valued at approximately $490,738.72. The trade was a 79.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Jr. Michael Conick Hanley also recently made the following trade(s):
- On Wednesday, November 18th, Jr. Michael Conick Hanley sold 2,896 shares of Alto Neuroscience stock. The stock was sold at an average price of $26.48, for a total value of $76,686.08.
- On Tuesday, November 17th, Jr. Michael Conick Hanley sold 2,104 shares of Alto Neuroscience stock. The shares were sold at an average price of $26.82, for a total value of $56,429.28.
Alto Neuroscience Stock Up 3.4%
ANRO stock traded up $0.85 during trading on Wednesday, hitting $25.77. The company had a trading volume of 986,145 shares, compared to its average volume of 597,641. The business has a 50-day moving average of $25.83 and a 200-day moving average of $24.79. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.12 and a current ratio of 18.12. Alto Neuroscience, Inc. has a one year low of $12.51 and a one year high of $37.48.
Alto Neuroscience (NYSE:ANRO – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.13. As a group, analysts expect that Alto Neuroscience, Inc. will post -2.48 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on ANRO shares. Wedbush increased their price objective on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. BTIG Research restated a “buy” rating and issued a $37.00 target price on shares of Alto Neuroscience in a report on Wednesday, November 11th. HC Wainwright reaffirmed a “buy” rating on shares of Alto Neuroscience in a research report on Thursday, November 12th. Zacks Research upgraded Alto Neuroscience from a “strong sell” rating to a “hold” rating in a report on Thursday, August 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a report on Tuesday, October 27th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.88.
Check Out Our Latest Stock Report on Alto Neuroscience
Hedge Funds Weigh In On Alto Neuroscience
A number of institutional investors and hedge funds have recently modified their holdings of ANRO. Bellevue Group AG acquired a new stake in shares of Alto Neuroscience during the 3rd quarter worth approximately $29,706,000. Spruce Street Capital LP increased its stake in shares of Alto Neuroscience by 494.7% in the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after acquiring an additional 1,102,366 shares in the last quarter. Commodore Capital LP increased its stake in shares of Alto Neuroscience by 49.4% in the 1st quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock valued at $61,217,000 after acquiring an additional 900,000 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Alto Neuroscience by 281.1% during the 3rd quarter. Marshall Wace LLP now owns 859,309 shares of the company’s stock valued at $21,938,000 after acquiring an additional 633,806 shares during the period. Finally, Affinity Asset Advisors LLC acquired a new position in shares of Alto Neuroscience during the 1st quarter valued at $11,240,000.
Alto Neuroscience Company Profile
Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.
Featured Articles
- Five stocks we like better than Alto Neuroscience
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
